Last month, Google-backed genomics giant 23andMe announced it would be enlisting the help of 20,000 volunteers – along with German pharma company Grünenthal – to carry out a major new study of the genetics of pain. The new study comes on the heels of results announced last year, when data from 450,000 of the company’s users was crunched by scientists from Massachusetts General Hospital and pharma giant Pfizer to reveal 17 genetic variations in 15 genes linked to the risk of self-reported depression.

Read full news article on Naked Security